Trinity Biotech
TRIB
20 hedge funds and large institutions have $7.7M invested in Trinity Biotech in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
16% more call options, than puts
Call options by funds: $85K | Put options by funds: $73K
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
5% less funds holding
Funds holding: 21 → 20 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
35% less capital invested
Capital invested by funds: $11.9M → $7.7M (-$4.21M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$360K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$210K |
| 3 |
Morgan Stanley
New York
|
+$75.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.1K |
| 5 |
LPL Financial
San Diego,
California
|
+$33.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$509K |
| 2 |
Renaissance Technologies
New York
|
-$337K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$75K |
| 4 |
Millennium Management
New York
|
-$44.5K |
| 5 |
NA
Navellier & Associates
Reno,
Nevada
|
-$33K |
TRIB Hedge Fund Activity: Q4 2021 in Review
20 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2021, worth a combined $7.7M — down 35% from $11.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRIB and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Hunter Associates Investment Management, adding an estimated $360K. The largest seller was Stonehill Capital Management, cutting an estimated $509K.
- 20 institutional investors held Trinity Biotech (TRIB) as of Q4 2021, down from 21 in Q3 2021.
- Funds reported $7.7M of Trinity Biotech stock for Q4 2021, down 35% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q4 2021 and 5 closed out, a net change of -1 holder.
- The largest Trinity Biotech buyer in Q4 2021 was Hunter Associates Investment Management, an estimated $360K added.
- The largest Trinity Biotech seller in Q4 2021 was Stonehill Capital Management, an estimated $509K sold.
Based on aggregated 13F filings for Q4 2021.